|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shridhar R, Almhanna K, Meredith KL,
Biagioli MC, Chuong MD, Cruz A and Hoffe SE: Radiation therapy and
esophageal cancer. Cancer Control. 20:97–110. 2013.PubMed/NCBI
|
|
3
|
Li S, Jiang S, Jiang W, Zhou Y, Shen XY,
Luo T, Kong LP and Wang HQ: Anticancer effects of crocetin in human
esophageal squamous cell carcinoma KYSE-150 cells. Oncol Lett.
9:1254–1260. 2015.PubMed/NCBI
|
|
4
|
Williams KJ, Telfer BA, Xenaki D, Sheridan
MR, Desbaillets I, Peters HJ, Honess D, Harris AL, Dachs GU, van
der Kogel A and Stratford IJ: Enhanced response to radiotherapy in
tumours deficient in the function of hypoxia-inducible factor-1.
Radiother Oncol. 75:89–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsiao HT, Xing L, Deng X, Sun X, Ling CC
and Li GC: Hypoxia-targeted triple suicide gene therapy
radiosensitizes human colorectal cancer cells. Oncol Rep.
32:723–729. 2014.PubMed/NCBI
|
|
6
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harada H, Inoue M, Itasaka S, Hirota K,
Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, et al:
Cancer cells that survive radiation therapy acquire HIF-1 activity
and translocate towards tumour blood vessels. Nat Commun.
3:7832012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sohda M, Ishikawa H, Masuda N, Kato H,
Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Sakurai H and
Kuwano H: Pretreatment evaluation of combined HIF-1alpha, p53 and
p21 expression is a useful and sensitive indicator of response to
radiation and chemotherapy in esophageal cancer. Int J Cancer.
110:838–844. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moon SY, Chang HW, Roh JL, Kim GC, Choi
SH, Lee SW, Cho KJ, Nam SY and Kim SY: Using YC-1 to overcome the
radioresistance of hypoxic cancer cells. Oral Oncol. 45:915–919.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Staab A, Fleischer M, Loeffler J, Said HM,
Katzer A, Plathow C, Einsele H, Flentje M and Vordermark D: Small
interfering RNA targeting HIF-1α reduces hypoxia-dependent
transcription and radiosensitizes hypoxic HT 1080 human
fibrosarcoma cells in vitro. Strahlenther Onkol. 187:252–259. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El Kaffas A, Al-Mahrouki A, Tran WT, Giles
A and Czarnota GJ: Sunitinib effects on the radiation response of
endothelial and breast tumor cells. Microvasc Res. 92:1–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cuneo KC, Geng L, Fu A, Orton D, Hallahan
DE and Chakravarthy AB: SU11248 (sunitinib) sensitizes pancreatic
cancer to the cytotoxic effects of ionizing radiation. Int J Radiat
Oncol Biol Phys. 71:873–879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun J, Sun Q, Brown MF, Dudgeon C,
Chandler J, Xu X, Shu Y, Zhang L and Yu J: The multi-targeted
kinase inhibitor sunitinib induces apoptosis in colon cancer cells
via PUMA. PloS One. 7:e431582012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsumoto S, Batra S, Saito K, Yasui H,
Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe
JP, Mitchell JB and Krishna MC: Antiangiogenic agent sunitinib
transiently increases tumor oxygenation and suppresses cycling
hypoxia. Cancer Res. 71:6350–6359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Xu X, Zhang L, Fu Y, Wang M, Gu H
and Xie X: Blocking autocrine VEGF signaling by sunitinib, an
anti-cancer drug, promotes embryonic stem cell self-renewal and
somatic cell reprogramming. Cell Res. 24:1121–1136. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shin HW, Cho CH, Kim TY and Park JW:
Sunitinib deregulates tumor adaptation to hypoxia by inhibiting
HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem Biophys
Res Commun. 398:205–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshimura M, Itasaka S, Harada H and
Hiraoka M: Microenvironment and radiation therapy. Biomed Res Int.
2013:6853082013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim DW, Huamani J, Fu A and Hallahan DE:
Molecular strategies targeting the host component of cancer to
enhance tumor response to radiation therapy. Int J Radiat Oncol
Biol Phys. 64:38–46. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sadri N and Zhang PJ: Hypoxia-inducible
factors: Mediators of cancer progression; prognostic and
therapeutic targets in soft tissue sarcomas. Cancers (Basel).
5:320–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martinive P, Defresne F, Bouzin C, Saliez
J, Lair F, Grégoire V, Michiels C, Dessy C and Feron O:
Preconditioning of the tumor vasculature and tumor cells by
intermittent hypoxia: Implications for anticancer therapies. Cancer
Res. 66:11736–11744. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dewhirst MW, Cao Y and Moeller B: Cycling
hypoxia and free radicals regulate angiogenesis and radiotherapy
response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Yang X, Zhang Q, Yang B, Xu L,
Qin Q, Zhu H, Liu J, Cai J, Tao G, et al: Berberine radiosensitizes
human nasopharyngeal carcinoma by suppressing hypoxia-inducible
factor-1alpha expression. Acta Otolaryngol. 134:185–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmitt JM, Sommers SR, Fisher W, Ansari
R, Robin E, Koneru K, McClean J, Liu Z, Tong Y and Hanna N:
Sunitinib plus paclitaxel in patients with advanced esophageal
cancer: A phase II study from the Hoosier Oncology Group. J Thorac
Oncol. 7:760–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen FH, Chiang CS, Wang CC, Fu SY, Tsai
CS, Jung SM, Wen CJ, Lee CC and Hong JH: Vasculatures in tumors
growing from preirradiated tissues: Formed by vasculogenesis and
resistant to radiation and antiangiogenic therapy. Int J Radiat
Oncol Biol Phys. 80:1512–1521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gaustad JV, Pozdniakova V, Hompland T,
Simonsen TG and Rofstad EK: Magnetic resonance imaging identifies
early effects of sunitinib treatment in human melanoma xenografts.
J Exp Clin Cancer Res. 32:932013. View Article : Google Scholar : PubMed/NCBI
|
